EP3481838

GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Application Number
EP17739936A
Filing Date
Jul 7, 2017
Status
Granted And Under Opposition
Jul 17, 2020
Grant Date
Aug 19, 2020
External Links
Slate, Register

Biblio Summary

The patent EP3481838B1 was granted on Aug 19, 2020 by Glaxosmithkline Intellectual Property Development Limited The patent is currently Granted And Under Opposition.

The table below shows 2 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

JANSSEN PHARMACEUTICA N.V.May 19, 2021ADMISSIBLE
JG OPPOSITIONS LIMITEDMay 19, 2021ADMISSIBLE

The table below shows the patents of Glaxosmithkline Intellectual Property Development Limited that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3650019Fluticasone Furoate In The Treatment Of CopdOct 11, 20233
EP3297605Topical Pharmaceutical CompositionsMay 4, 20221
EP3461474Dry Powder Inhalation Drug Products Exhibiting Moisture Control Properties And Methods Of Administering The SameNov 11, 20204

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.